Introduction
============

Upper urinary tract urothelial carcinoma (UTUC) accounts for \~5% of all urothelial tumors and 10% of all renal tumors ([@b1-ol-06-04-1015]). Since the disease recurrence and progression rates are high in patients with UTUC ([@b2-ol-06-04-1015]), an improved understanding of the prognostic parameters may lead to the identification of patients who may benefit from intensified therapy and monitoring.

The classical risk factors for the development of UTUC include smoking, abuse of analgesics, chronic urinary tract infection, urolithiasis and oncological agents, such as cyclophosphamide ([@b3-ol-06-04-1015]). A significant prognostic factor of UTUC is the disease stage. The five-year survival rate for low stage tumors is \~90%, which decreases to \<30% in cases of regional nodal metastases and to \<10% in cases of distant metastases ([@b4-ol-06-04-1015]).

To date, several contemporary, single-center studies of patients who were treated with radical nephroureterectomy (RNU) for UTUC have been published ([@b5-ol-06-04-1015]--[@b9-ol-06-04-1015]), and several risk factors for developing UTUC have been reported, including a delay in the RNU ([@b10-ol-06-04-1015]) and tumor necrosis ([@b11-ol-06-04-1015]). Although the studies have largely contributed to our understanding of the disease, they were limited by small and heterogeneous populations. To overcome this limitation and to improve our understanding of the natural history of UTUC, a comprehensive database \[the Upper Tract Urothelial Carcinoma Collaboration (UTUCC)\] incorporating the clinicopathological characteristics and outcomes of \>1,300 patients treated with RNU for UTUC at 13 academic centers worldwide was created in 2008 ([@b12-ol-06-04-1015]). It was concluded that an RNU provided durable local control and cancer-specific survival (CSS) in patients with a localized UTUC, and that the pathological tumor grade, T stage, lymph node status, tumor architecture and lymphovascular invasion (LVI) were significant prognostic variables that were associated with oncological outcomes, which may potentially be used to select patients for adjuvant systemic therapy.

However, there have been no studies that considered the prognostic value of urothelial recurrence in patients with UTUC of the kidney and ureter that is managed by surgery. Consequently, the present study focused on the prognostic impact of urothelial recurrence in comparison with non-urothelial recurrence.

Patients and methods
====================

Patient selection
-----------------

The present study was a retrospective analysis of 153 consecutive patients with UTUC, who underwent surgery between 1996 and 2009 at Hirakata City Hospital (Osaka, Japan). Of the 153 patients that were screened for the study, 103 patients were included in the analysis. The inclusion criteria consisted of a diagnosis of non-metastatic UTUC (any T stage, N0--1 and M0) and receipt of an RNU with an ipsilateral bladder cuff as the primary treatment. No patient had an invasive bladder tumor (BT) at the time of the RNU. Written informed consent was obtained from the patient. This study was approved by the ethics committee of Hirakata City Hospital (Osaka, Japan).

In the past, open RNU using an open excision of the distal ureter with a bladder cuff has been performed to dissect the kidney, with the entire length of the ureter and an adjacent segment of the bladder cuff. From June 2003 to date, the approach that has been used is one of conventional four-trocar nephrectomy. Once the nephrectomy is completed, the ureter is dissected and the intact specimen is moved into the pelvis. Next, a semi-Pfannenstiel incision is made in the lower abdomen, which assists in retrieving the specimen, eases the dissection of the lower ureter and facilitates the excision of the bladder cuff. The hilar and regional lymph nodes that are adjacent to the ipsilateral great vessel are then resected, if possible.

Study design
------------

The following clinical and pathological variables were evaluated: Gender, age, tumor side, presence of a BT at diagnosis, serum level of C-reactive protein, hemoglobin, histological type, pathological grade, adjuvant chemotherapy, microvascular invasion, lymphatic invasion, urothelial recurrence, non-urothelial recurrence and pathological stage (2002 TNM system). The tumor grading was assessed according to the 1998 World Health Organization/International Society of Urologic Pathology consensus classification ([@b13-ol-06-04-1015]). All surgical specimens were processed according to the standard pathological procedures at the Hirakata City Hospital. UTUC was defined as a urothelial carcinoma located in the renal pelvis or calices, as well as tumors located within the ureter. C-reactive protein was pre-operatively obtained from the blood of the UTUC patients and collected in a serum-separating tube. The C-reactive protein level was expressed in units of mg/dl. Microvascular invasion was defined as tumor cells in an endothelium-lined space observed using routine light microscopy in whole-mounted UTUC specimens. The oncological follow-up schedule included a physical examination, cystoscopy and CT imaging between the chest and pelvis twice per year during the first five years and annually thereafter.

Statistical analysis
--------------------

The continuous parametric variables were reported as mean ± SD and range. The continuous non-parametric variables were presented as median values and interquartile ranges. The F test was used to assess whether the standard deviations of two populations were equal. χ^2^ tests were conducted to assess the differences in the covariate distributions between the urothelial and non-urothelial recurrence categories. CSS was defined as the primary endpoint of the study. The survival interval was defined as the time elapsed between the surgery and the last clinical evaluation or cancer-specific mortality. Survival curves were estimated using the Kaplan-Meier method. The patients who remained alive or succumbed to other causes were censored. The log-rank test was used to compare the survival curves. A Cox proportional hazards regression model was used to verify the clinicopathological variables that independently predicted CSS. In all statistical analyses, a two-sided value of P\<0.05 was considered to indicate a statistically significant difference. All data were analyzed using the PASW Statistics version 17 statistical program (SPSS Japan Inc., Tokyo, Japan).

Results
=======

A total of 103 patients with comprehensive clinicopathological data, who fulfilled the inclusion criteria, were included in the analysis ([Table I](#tI-ol-06-04-1015){ref-type="table"}). The mean age was 68.6 years (interquartile range, 62--75 years). During the follow-up period, 45 patients (43.7%) succumbed to UTUC, 12 (11.7%) succumbed to other causes and 38 (36.9%) displayed evidence of disease recurrence. The median follow-up period for the surviving patients was 29 months (interquartile range, 14--63 months). The tumor was located on the right side in 55 patients (53.4%) and on the left side in 48 (46.6%). A BT was identified at the time of the UTUC diagnosis in 28 patients (27.2%). The histological type was urothelial in 92 patients (89.3%) and non-urothelial in 11 (10.7%). The pathological stage was divided into three groups: Superficial (pT0/pTis/pTa/pT1), muscle-invasive (pT2) and non-organ confined (pT3/pT4), which were identified in 43 (41.8%), 13 (12.6%) and 47 (45.6%) patients, respectively.

The median ages of the patients at the time of the surgery in the groups with non-urothelial recurrence (n=32) and without non-urothelial recurrence (n=71) were 70.5 and 69 years, respectively. The median ages in the groups with urothelial recurrence (n=38) and without urothelial recurrence (n=65) were 69 and 71 years, respectively. When comparing the risk parameters between the non-urothelial recurrence categories, the factors of pathological grade, microvascular invasion, lymphatic invasion and pT classification demonstrated significant differences. However, there were no significant differences observed between the urothelial recurrence categories.

The OS and CSS times between the urothelial recurrence categories showed no significant differences (P=0.3955 and P=0.05891, respectively), while a significant difference was observed within the non-urothelial recurrence categories (P\<0.0001 and P\<0.0001, respectively; [Figs. 1](#f1-ol-06-04-1015){ref-type="fig"}--[4](#f4-ol-06-04-1015){ref-type="fig"}).

The univariate analyses using the clinicopathological characteristics, including C-reactive protein, hemoglobin, pathological grade, non-urothelial recurrence, microvascular invasion, lymphatic invasion and pT classification, were associated with the CSS. In the multivariate analysis for the clinicopathological characteristics, only non-urothelial recurrence was associated with a worse CSS (P=0.002, HR 9.512; [Table II](#tII-ol-06-04-1015){ref-type="table"}).

Discussion
==========

UTUC is a relatively rare malignancy. Although affected patients may benefit from endoscopic or nephron-sparing approaches, an RNU with an ipsilateral bladder cuff excision remains the standard treatment for patients with large, multifocal or high-grade tumors. However, despite definitive surgery, UTUC remains a malignancy with a high potential for local and distant recurrence, particularly in patients with advanced diseases ([@b14-ol-06-04-1015]). The outcomes of patients with UTUC following an RNU are heterogeneous and, therefore, difficult to predict. Multi-institutional collaborative studies have identified several potential factors that predict the outcome following an RNU for UTUC, supplementing the traditional pathological staging system ([@b15-ol-06-04-1015]--[@b17-ol-06-04-1015]).

Certain papers have examined the prognostic value of urothelial recurrence (particularly intravesical recurrence) following the treatment of an RNU for UTUC. Koda *et al* reported that intravesical recurrence following surgery for UTUC was not associated with the mode of surgery (i.e. laparoscopy-assisted or open surgery), and that the only risk factor for intravesical recurrence was a history of bladder cancer ([@b18-ol-06-04-1015]). Several other studies reported that it may be important to perform careful follow-up appointments that target intravesical recurrence for patients, particularly males and those with low-stage tumors and/or multifocal tumors, following RNU ([@b19-ol-06-04-1015], [@b20-ol-06-04-1015]). Concomitant carcinoma *in situ* (CIS) and the tumor size were predictors for bladder cancer recurrence ([@b21-ol-06-04-1015]). In a series of 196 patients, bladder recurrence was lower in those who received mitomycin C or epirubicin compared with those who did not received anything (29.0, 25.9 and 41.3%, respectively) ([@b22-ol-06-04-1015]). Novara *et al* observed that only a history of bladder cancer prior to an RNU was an independent risk factor for metachronous recurrence, which was identified in 6% of patients ([@b23-ol-06-04-1015]). Youssef *et al* underlined the prognostic impact of previous bladder cancer ([@b24-ol-06-04-1015]); patients with a positive bladder cancer (CIS) history had a greater risk of recurrence and mortality from UTUC following RNU ([@b24-ol-06-04-1015]).

The common locations for the spread of UTUC, depending on the site of the primary tumor, include para-aortic, paracaval, ipsilateral common iliac and pelvic lymph nodes. Hematogenous seeding also occurs in the liver, lungs and bone, which are common sites for metastases. Once a distant metastasis is diagnosed, the prognosis for the patient is extremely poor, in spite of chemotherapy. Certain publications suggest a benefit from the surgical removal of urothelial carcinoma metastases for a subgroup of patients ([@b25-ol-06-04-1015]). In a large German retrospective study, only 44 patients with distant metastases of the bladder or upper urinary tract underwent a complete resection of all the detectable metastases and were analyzed. The resected metastatic sites included the retroperitoneal lymph nodes (56.8%), distant lymph nodes (11.3%), lung (18.2%), bone (4.5%), adrenal gland (2.3%), brain (2.3%), small intestine (2.3%) and skin (2.3%). Pre- and/or post-metastasectomy systemic chemotherapy was administered in 35 of 44 patients (79.5%). Since no significant prognostic factors were determined due to the limited patient numbers, it was concluded that the metastasectomy in the patients with disseminated urothelial carcinoma metastases remained investigational and there are a limited number of disease types for which a combined-modality approach with systemic chemotherapy would be successful ([@b26-ol-06-04-1015]).

Lymph node dissection (LND) appears to have an impact on node-positive patients ([@b27-ol-06-04-1015]). In one previous study, 76 out of 293 patients developed disease relapse. Regional lymph node recurrence was the most common type of relapse (34 patients). In the multivariate analyses that adjusted for the effect of tumor stage and grade, pNx (skipping LND) was an adverse factor for locoregional recurrence and distant relapse ([@b28-ol-06-04-1015]). However, in the study by Lughezzani *et al*, which analyzed 2,824 patients from the Surveillance, Epidemiology and End Results (SEER) database, LND showed no benefit in patients with an N0 status compared with those with an Nx status ([@b29-ol-06-04-1015]). Roscigno *et al* suggested that LND should be performed in patients with suspected T2--4 stage diseases, to improve the prediction of the natural history of surgically treated UTUC and to use this information for possible adjuvant chemotherapy ([@b30-ol-06-04-1015]). Thus, the method of defining the right patient, LND template and the extent of the LND remains unclear.

The present study examined the prognostic value of urothelial and non-urothelial recurrence in patients with UTUC of the kidney and ureter that was managed by surgery. The OS and CSS times between the urothelial recurrence categories showed no significant differences, while significant differences were observed in the OS and CSS between the non-urothelial recurrence categories. The factors of pathological grade, microvascular invasion, lymphatic invasion and pT classification significantly affected the non-urothelial recurrence. However, no factors were observed to significantly affect the urothelial recurrence. In the multivariate analysis for clinicopathological characteristics, only non-urothelial recurrence remained associated with a worse CSS. The present data are limited by the retrospective nature of the study and the relatively small cohort. Prospective studies are required to confirm these findings. However, it may be concluded that non-urothelial recurrence significantly affected the prognosis in patients with UTUC managed by RNU with an ipsilateral bladder cuff compared with those with urothelial recurrence. The findings of the present study underscore the requirement for the careful follow-up and management of urothelial recurrence in patients with UTUC managed by RNU, which aids in lowering the risk of mortality due to cancer.
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###### 

Clinicopathological characteristics grouped by non-urothelial or urothelial recurrence in 103 patients treated with an RNU and ipsilateral bladder cuff for UTUC.

                                           Non-urothelial recurrence   Urothelial recurrence                             
  ------------------------------- -------- --------------------------- ----------------------- ------- -------- -------- -------
  Number of patients              103      32                          71                              38       65       
  Gender, n                                                                                    0.819                     0.511
   Male                           71       23                          48                              28       43       
   Female                         32       9                           23                              10       22       
  Age, years                                                                                   0.788                     0.138
   Mean                           68.6     70.3                        67.8                            67.3     71.0     
   SD                             10.1     9.3                         10.4                            10.2     9.4      
   Median                         69.0     70.5                        69.0                            69.0     71.0     
   Range                          23--91   51--91                      23--87                          23--87   54--91   
  Tumor side, n                                                                                0.400                     0.221
   Right                          55       15                          40                              17       38       
   Left                           48       17                          31                              21       27       
  BT at diagnosis, n                                                                           0.399                     0.255
   Yes                            28       11                          17                              13       15       
   No                             75       21                          54                              25       50       
  C-reactive protein (mg/ml), n                                                                0.282                     0.432
   \<0.3                          60       16                          44                              23       37       
   ≥0.3                           43       16                          27                              15       28       
  Hemoglobin (mg/ml), n                                                                        0.599                     0.614
   ≤NR                            75       14                          61                              27       48       
   \>NR                           28       18                          10                              11       17       
  Histological type, n                                                                         0.166                     0.865
   Urothelial                     92       24                          68                              32       60       
   Non-urothelial                 11       8                           3                               6        5        
  Pathological grade, n                                                                        0.008                     0.278
   1                              20       3                           17                              4        16       
   2                              28       5                           23                              12       16       
   3                              55       24                          31                              22       33       
  Adjuvant chemotherapy, n                                                                     0.508                     0.756
   Yes                            12       5                           7                               5        7        
   No                             91       27                          64                              33       55       
  Microvascular invasion, n                                                                    0.001                     0.214
   Absent                         69       13                          56                              23       46       
   Present                        34       19                          15                              15       19       
  Lymphatic invasion, n                                                                        0.005                     0.654
   Absent                         71       17                          54                              24       47       
   Present                        32       15                          17                              14       18       
  pT classification, n                                                                         0.001                     0.209
   pT0/pTis/pTa/pT1               43       6                           37                              15       28       
   pT2                            13       2                           11                              2        11       
   pT3/pT4                        47       24                          23                              21       26       

RNU, radical nephroureterectomy; UTUC, upper tract urothelial carcinoma; BT, bladder tumor; NR, normal range; pT0/pTis/pTa/pT1, superficial; pT2, muscle invasive; pT3/pT4, non-organ defined.

###### 

Univariate and multivariate Cox regression models for clinicopathological characteristics predicting CSS in 103 patients treated with RNU and ipsilateral bladder cuff for UTUC.

                               Univariate   Multivariate                                        
  ---------------------------- ------------ --------------- ----------- ------- --------------- -------
  Gender                                                                                        
   Male                        Reference                    Reference                           
   Female                      0.906        0.467--1.758    0.771       0.945   0.318--2.805    0.919
  Age                                                                                           
   Continuous                  1.001        0.971--1.033    0.928       0.998   0.922--1.080    0.954
  Tumor side                                                                                    
   Right                       Reference                    Reference                           
   Left                        0.686        0.379--1.241    0.213       0.475   0.172--1.312    0.151
  BT at diagnosis                                                                               
   Yes                         Reference                    Reference                           
   No                          1.014        0.498--1.952    0.968       2.494   0.089--1.794    0.232
  C-reactive protein (mg/ml)                                                                    
   Continuous                  1.184        1.095--1.281    0.000       1.189   0.933--1.516    0.161
  Hemoglobin (mg/ml)                                                                            
   Continuous                  1.203        0.732--0.944    0.004       1.133   0.685--1.138    0.337
  Histological type, n                                                                          
   Urothelial                  Reference                    Reference                           
   Non-urothelial              2.036        0.924--4.486    0.078       1.951   0.409--9.320    0.402
  Pathological grade, n                                                                         
   1/2                         Reference                    Reference                           
   3                           4.918        1.984--12.191   0.001       2.288   0.266--19.705   0.451
  Adjuvant chemotherapy                                                                         
   Yes                         Reference                    Reference                           
   No                          1.183        0.333--2.144    0.723       1.499   0.149--2.989    0.597
  Urothelial recurrence                                                                         
   No                          Reference                    Reference                           
   Yes                         0.929        0.511--1.690    0.809       0.648   0.215--1.956    0.442
  Non-urothelial recurrence                                                                     
   No                          Reference                    Reference                           
   Yes                         5.750        3.018--10.954   0.000       9.512   2.293--39.464   0.002
  Microvascular invasion, n                                                                     
   Absent                      Reference                    Reference                           
   Present                     8.299        3.909--17.618   0.000       3.551   0.585--21.558   0.168
  Lymphatic invasion, n                                                                         
   Absent                      Reference                    Reference                           
   Present                     3.953        1.966--7.947    0.000       1.205   0.319--4.553    0.784
  pT classification, n                                                                          
   pT0/pTis/pTa/pT1            Reference                    Reference                           
   pT2/pT3/pT4                 2.619        1.676--4.092    0.000       0.996   0.275--3.611    0.995

CSS, cancer-specific survival; RNU, radical nephroureterectomy; HR, hazard ratio; UTUC, upper tract urothelial carcinoma; pT0/pTis/pTa/pT1, superficial; pT2/pT3/pT4, muscle invasive/non-organ defined.
